Compare Bristol-Myers Squibb Co (BMY) vs iShares Core MSCI Emerging Markets ETF (IEMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs iShares Core MSCI Emerging Markets ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.7 (market cap $129.94B), while iShares Core MSCI Emerging Markets ETF trades at $81.03. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while iShares Core MSCI Emerging Markets ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, iShares Core MSCI Emerging Markets ETF nearer its low. Which is the better fit depends on your goals.
| BMY | IEMG | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $65.89 | $86.00 |
52-Week Low | $42.60 | $61.76 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
IEMG trades at $81.02, up 1.84% today with a bullish technical signal from moving averages. The ETF shows strong momentum with 35% returns over the past year, driven by emerging market exposure and a 40% technology weighting focused on AI themes. Recent news highlights IEMG's outperformance versus developed market ETFs and its competitive 0.09% expense ratio.
Outlook remains positive given emerging market growth potential and AI-driven tech exposure, though risks include concentration in volatile emerging economies and elevated RSI levels suggesting potential near-term consolidation. The ETF's valuation discount to US equities and strong institutional inflows support continued investor interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →
